Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, December 1, 2021
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
[ Wed, Dec 01st 2021
] - WOPRAI
Tue, November 30, 2021
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
[ Tue, Nov 30th 2021
] - WOPRAI
Patrick Trucchio Maintained (VIR) at Strong Buy with Increased Target to $200 on, Nov 30th, 2021
Patrick Trucchio of HC Wainwright & Co., Maintained "Vir Biotechnology, Inc." (VIR) at Strong Buy with Increased Target from $135 to $200 on, Nov 30th, 2021.
Patrick has made no other calls on VIR in the last 4 months.
There are 3 other peers that have a rating on VIR. Out of the 3 peers that are also analyzing VIR, 2 agree with Patrick's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Increased Target to $37 on, Monday, October 25th, 2021
- Paul Choi of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $62 on, Wednesday, September 22nd, 2021
This is the rating of the analyst that currently disagrees with Patrick
- Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $71 on, Friday, August 6th, 2021
